Needham Starts Artiva Biotherapeutics (ARTV) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ARTV Hot Sheet
Price: $4.20 --0%
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 24 | New: 12
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 24 | New: 12
Join SI Premium – FREE
Needham analyst Gil Blum initiates coverage on Artiva Biotherapeutics (NASDAQ: ARTV) with a Buy rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Artiva Biotherapeutics click here. For more ratings news on Artiva Biotherapeutics click here.
Shares of Artiva Biotherapeutics closed at $11.22 yesterday.
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Bernstein SocGen Group Starts Pfizer Ltd (PFIZ:IN) at Outperform
- Goldman Sachs Assumes Skyworks Solutions (SWKS) at Sell
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
